Toni Choueiri, MD· @DrChoueiri · X·· 2 days agoScore70
Body
Post-IO RCC update by @DrDanielHeng in LITESPARK-011 Ph.III:
Bel/Len vs Cabo maintained PFS benefit (14.8 vs 10.8 mo; HR 0.74).
ORR 53% vs 40%; DOR 22 vs 12 mo.
OS favored Bel/Len (33.7 vs 28.6 mo; HR 0.85) but missed significance boundary.
#ESMO26 #RCC @myESMO @OncoAlert
198 views · 6 likes · 5 reposts · 0 replies
Source: Toni Choueiri, MD · x.com
